Related Experiment Video
Updated: May 5, 2026

Voluntary Breath-hold Technique for Reducing Heart Dose in Left Breast Radiotherapy
Published on: July 3, 2014
Cardiovascular Considerations After Cancer Therapy: Gaps in Evidence and JACC: CardioOncology Expert Panel
Anne Blaes1, Anju Nohria2,3, Saro Armenian4
1Division of Hematology/Oncology/Transplantation, University of Minnesota, Minneapolis, Minnesota, USA.
Abstract:
Cancer survivors, particularly those treated with anthracyclines and chest radiation, face an elevated risk of cancer therapy-related cardiovascular toxicity. These complications affect not only physical health, but also life expectancy. Risk factors for cancer therapy-related cardiovascular toxicity include age at which cancer treatment was received, the use of (potentially) cardiotoxic cancer therapies, and the presence of concomitant cardiovascular risk factors. Current guidelines provide recommendations for cardiovascular surveillance after cancer therapy, including type and frequency. All cancer survivors are advised to undergo annual clinical screenings and optimization of cardiovascular risk factors. Those at higher risk should undergo additional cardiovascular testing. This document aims to summarize the available evidence, present practical recommendations, and outline existent gaps in the current literature regarding cardiovascular care after cancer therapies.
More Related Videos
Related Concept Videos
Cardiovascular Drugs: Classification based on Therapeutic Indications
Coronary Artery Disease IV: Preventive Measures
Coronary Artery Disease V: Interprofessional Care
Cardiomyopathy V: Interprofessional Care
Cardiomyopathy VI: Nursing Management
Cardiomyopathy VII: Pre and Post Operative Nursing Management

